ACHV
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Achieve Life Sciences, Inc. (ACHV) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Profitability (F). The rating has held at C for 14 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-10 | C+ (2.5) | C+ (2.8) | F (0.4) | B+ (3.7) | C+ (2.6) | C (2.4) |
| 2026-11-03 | C+ (2.5) | C+ (2.8) | F (0.4) | A- (3.9) | C+ (2.7) | C (2.4) |
| 2026-10-27 | C+ (2.5) | C+ (2.7) | F (0.4) | A- (3.9) | C+ (2.6) | C (2.4) |
| 2026-10-20 | C+ (2.5) | C+ (2.7) | F (0.4) | B+ (3.7) | C+ (2.6) | C (2.4) |
| 2026-10-13 | C+ (2.5) | C+ (2.7) | F (0.4) | A- (3.9) | C+ (2.6) | C (2.4) |